ANIP — ANI PHARMACEUTICALS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1023024 ·
Last close
$74.17
Market Cap
$1.70B
52W High
$87.19
52W Low
$73.27
ADV30
340,432
Next earnings
2026-11-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 266,044,000 | 165,886,000 | 39,838,000 | 24,711,000 | 1,494,112,000 | 360,212,000 | 896,900,000 |
| Mar 2026 | 237,462,000 | 143,880,000 | 38,706,000 | 29,492,000 | 1,421,970,000 | 311,176,000 | 859,670,000 |
| Dec 2025 | 247,060,000 | 146,791,000 | 29,127,000 | 27,490,000 | 1,440,377,000 | 285,585,000 | 899,653,000 |
| Sep 2025 | 227,813,000 | 134,424,000 | 22,832,000 | 26,617,000 | 1,408,152,000 | 262,610,000 | 902,335,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$208,609,000
Investing CF
$-25,799,000
Financing CF
$-21,654,000
CapEx
$-25,799,000
Dividends Paid
$-751,000
Buybacks
$-29,758,000
EPS Diluted TTM
$3.95
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$6,393,000
Inventory
$143,468,000
Receivables
$255,432,000
ST Investments
$14,885,000
EBIT TTM
$134,370,000
Pretax Income TTM
$116,025,000
Interest Exp TTM
$18,345,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$978,379,008
EBITDA
$209,407,008
Free Cash Flow
$132,205,752
Enterprise Value
$1,838,491,136
Total Cash
$376,961,984
Total Debt
$626,028,032
Shares Out
22,959,488
Trailing EPS
$4.52
Book Value
$27.87
ROE
20.5%
ROA
5.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 883,366,000 | 81,230,000 | 78,337,000 | 1,440,377,000 | 899,653,000 | — | 185,225,000 |
| Dec 2024 | 614,376,000 | 2,218,000 | -18,522,000 | 1,284,469,000 | 855,939,000 | — | 64,017,000 |
| Dec 2023 | 486,816,000 | 49,529,000 | 18,779,000 | 904,422,000 | 446,823,000 | — | 118,959,000 |
| Dec 2022 | 316,385,000 | -25,734,000 | -47,896,000 | 760,087,000 | 421,547,000 | — | -31,203,000 |
TTM Snapshot
Revenues TTM
$416,043,000
NetIncome TTM
$-27,273,000
OpCashFlow TTM
$0
Assets (Latest)
$1,283,697,000
Forward EPS
$10.54
Max Pain — expiry 2026-10-16
max pain strike: $85.00 · spot: $74.17 · call oi: 3,099 · put oi: 2,203
Expected Move to 2026-10-16:
±$8.30
(11.19%) —
implied range
$65.87 –
$82.47
· ATM straddle on $75.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GLPGF | Lakefront Biotherapeutics NV | $1.72B | $26.24 | — |
| ANAB | ANAPTYSBIO, INC | $1.73B | $58.44 | — |
| SNDX | Syndax Pharmaceuticals Inc | $1.73B | $19.57 | — |
| AVLN | Avalyn Pharma Inc. | $1.67B | $37.69 | — |
| FBRX | Forte Biosciences, Inc. | $1.63B | $76.95 | — |
News headlines (Yahoo Finance, 1h cache)
ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors
2026-08-24 10:55 · Yahoo
The Top 5 Analyst Questions From ANI Pharmaceuticals’s Q2 Earnings Call
2026-08-16 09:09 · Yahoo
Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk?
2026-08-14 17:15 · Yahoo
ANI Pharmaceuticals (ANIP) Q2 2026 Earnings Call Transcript
2026-08-14 13:14 · Yahoo
ANIP Q2 Deep Dive: Rare Disease Expansion Drives Growth Amid Guidance Recalibration
2026-08-11 13:33 · Yahoo
ANI Pharmaceuticals (ANIP) Could Be 31% Undervalued On Strong Q2 Results And Guidance Reset
2026-08-08 19:09 · Yahoo
ANI Pharmaceuticals Inc (ANIP) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic ...
2026-08-07 19:01 · Yahoo
ANI Pharmaceuticals Q2 Earnings Call Highlights
2026-08-07 14:04 · Yahoo
ANI Pharmaceuticals Shares Slide Despite Earnings Beat After Cortrophin Outlook Cut
2026-08-07 13:59 · Yahoo
ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Beat Estimates
2026-08-07 12:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.